Anurag Relan, MD
Pharming Technologies BV · VP Clinical Research & Medical Affairs at Pharming · Pharming Group N.V.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anurag Relan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04912141 · Prevention of Acute Kidney Injury in Patients With NSTEMIPharming Technologies B.V. · terminated · Non-ST Elevation Myocardial Infarction (NSTEMI) · study director
- N/ANCT03697187 · Patient Registry to Evaluate the Real-world Safety of Ruconest®Pharming Technologies B.V. · completed · Hereditary Angioedema · study director
- N/ANCT01397864 · C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksPharming Technologies B.V. · completed · Hereditary Angioedema · study director
- Ph2NCT01359969 · Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsPharming Technologies B.V. · completed · Hereditary Angioedema · study director
- Ph2/Ph3NCT00225147 · Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaPharming Technologies B.V. · completed · Hereditary Angioedema, Angioneurotic Edema · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.